ArticleJCO precision oncology2025

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors.

Geraldine O'Sullivan Coyne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.